EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design and optimization of mRNAs encoding an Anti-TIGIT antibody with therapeutic potential for cancer in TIGIT-humanized BALB/c Mice

Jingmin Cui, Gulisaina Qiaerxie, Hui Qin, Feng Long, Xi Wang, Zhixin Yang, Peng Du, Yong Cui

Archives of Pharmacy and Pharmaceutical Sciences · 07.04.2023 · 7 (1) · 008-016

DOI: 10.29328/journal.apps.1001038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Pharmacy and Pharmaceutical Sciences, online erschienen am 07.04.2023. Verfasst von Jingmin Cui und 7 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA drugs are synthesized using cell-free systems without complex and stringent manufacturing processes, which makes their preparation simple, efficient, and economical. Over the past few years, mRNAs encoding antibodies have been one of the research frontiers of antibody drug development. In cancer immunotherapy, mRNAs encoding immune checkpoint antibodies may be advantageous regarding antibody persistence and durability of the anti-tumor immune response of patients. In our previous study, a candidate antibody—AET2010—targeting the novel immune checkpoint TIGIT was reported. Its anti-tumor activity was also investigated using adoptive transfer of NK-92MI cells in a xenograft mouse model, but the limitations of the model did not facilitate precise evaluation. In the present study, we further investigated the therapeutic potential of AET2010 for cancer in TIGIT-humanized BALB/c mice. Next, we explored the design, synthesis, and optimization of mRNAs encoding AET2010 and ultimately obtained a candidate mRNA (mRNA-BU) with favorable in vitro and in vivo expression levels of active AET2010. Particularly, lipid-nanoparticle-encapsulated mRNA-BU delivered to mice produced AET2010 with significantly higher peak concentration and expression duration than an equivalent dose of original AET2010. This study provides a sound basis for developing novel drugs targeting TIGIT.

Zitieren

APA

Cui, J., Qiaerxie, G., Qin, H., Long, F., Wang, X., Yang, Z., Du, P., & Cui, Y. (2023). Design and optimization of mRNAs encoding an Anti-TIGIT antibody with therapeutic potential for cancer in TIGIT-humanized BALB/c Mice. Archives of Pharmacy and Pharmaceutical Sciences, 7(1), 008-016. https://doi.org/10.29328/journal.apps.1001038

Vancouver

Cui J, Qiaerxie G, Qin H, Long F, Wang X, Yang Z, et al. Design and optimization of mRNAs encoding an Anti-TIGIT antibody with therapeutic potential for cancer in TIGIT-humanized BALB/c Mice. Archives of Pharmacy and Pharmaceutical Sciences. 2023;7(1):008-016. doi:10.29328/journal.apps.1001038

BibTeX
@article{Cui2023,
  author = {Cui, Jingmin and Qiaerxie, Gulisaina and Qin, Hui and Long, Feng and Wang, Xi and Yang, Zhixin and Du, Peng and Cui, Yong},
  title = {Design and optimization of mRNAs encoding an Anti-TIGIT antibody with therapeutic potential for cancer in TIGIT-humanized BALB/c Mice},
  journal = {Archives of Pharmacy and Pharmaceutical Sciences},
  year = {2023},
  volume = {7},
  number = {1},
  pages = {008--016},
  doi = {10.29328/journal.apps.1001038}
}
Kostenlos starten →